Phospholipid remodeling and Parkinson's disease
10.16438/j.0513-4870.2022-0294
- VernacularTitle:磷脂重塑与帕金森病
- Author:
Meng WANG
1
;
Hiroshi KURIHARA
1
;
Yi-fang LI
1
;
Wen-jun DUAN
1
;
Rong-rong HE
1
Author Information
1. Guangdong Engineering Research Center of Chinese Medicine and Disease Susceptibility, Jinan University, Guangzhou 510632, China; Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, China; Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou 510632, China
- Publication Type:Research Article
- Keywords:
phospholipid remodeling;
Parkinson's disease;
calcium-independent phospholipase A2;
peroxiredoxin 6;
italic>α-synuclein;
mitochondrion
- From:
Acta Pharmaceutica Sinica
2022;57(6):1557-1564
- CountryChina
- Language:Chinese
-
Abstract:
The remodeling of phospholipid includes two processes: deacylation and reacylation. It realizes the conversion of nascent phospholipids to mature phospholipids by changing the length and types of fatty acids at specific sites of phospholipids, which is a key step in phospholipid metabolism. Phospholipids are not only the basic components of biological membranes, but also participate in the transduction of many molecular signals in cells. Therefore, phospholipid remodeling disorders can affect the structure and function of cell membranes, as well as the activity of membrane proteins, causing a series of intricate signaling cascades, and finally lead to many pathological changes including neurodegeneration. This paper reviews the basic process of phospholipid remodeling and the involvement of its key enzymes, calcium independent group VIA phospholipase A2 (iPLA2β), peroxiredoxin 6 (PRDX6), calcium independent group VIB phospholipase A2 (iPLA2γ) as well as acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) in the pathology of Parkinson's disease. The mutations in the gene encoding iPLA2β, PLA2G6, have been widely reported to be directly related to hereditary Parkinson disease-14 (PARK14). Here we focus on the molecular mechanism of iPLA2β in the development of Parkinson's disease, mainly involving phospholipid fatty acid metabolism disorders, mitochondrial physiology abnormalities and α-synuclein aggregate formation and other aspects, which will help to understand the role of phospholipid remodeling in Parkinson's disease, and provide new clues for the development of new Parkinson's disease diagnosis and treatment strategies.
